Abstract: A protein product and an extraction method for making the protein product. Raw materials of the product optionally contains macromolecular carbohydrates and/or fat, and the method does not use organic solvents. The protein product contains prolamin and carbohydrates, wherein the prolamin accounts for 70 wt % or above of the protein (dry-basis), the ?-prolamin accounts for 75 wt % or above of the prolamin, the ?-prolamin accounts for 20 wt % or below of the prolamin, and the ?-prolamin accounts for 6 wt % or below of the prolamin.

Abstract: The present application provides a composition for inducing chondrogenesis comprising an Wnt antagonist and a pharmaceutically acceptable carrier. The present application also provides a method for inducing chondrogenesis comprising administering an Wnt antagonist and a pharmaceutically acceptable carrier to a subject. The present application further provides a method for treating a cartilage-related disease comprising administering a therapeutically effective amount of an Wnt antagonist and a pharmaceutically acceptable carrier to a subject.

Abstract: A focused ultrasound device and method for dermatological treatment. The focused ultrasound device includes a focused ultrasound applicator, an automatic motion mechanism, a driver, a computer, a software operation interface. In addition, the focused ultrasound method for dermatological treatment utilizes the same focused ultrasound applicator, to achieve coaxial deep layer and shallow layer ablation treatment of the skin.

Abstract: A target particle transferring device is disclosed, which comprises: (a) a substrate with a thickness of T and a width of W, having top and bottom portions, the top portion having a top surface and the bottom portion having a bottom surface; (b) a notch structure formed in the bottom portion of the substrate, comprising: a groove with a width of W1, located at a distance oft below the top surface of the substrate, wherein the groove is formed in the bottom portion from the bottom surface extending toward the top portion; and (c) a target substrate portion with a width of W2 and a thickness of T, located in the top and bottom portions of the substrate and being surrounded by the groove. Methods of transferring a target particle from one device to another is also disclosed.

Abstract: An electronic device and a method for predicting a blockage of a coronary artery are provided. The method includes: obtaining multiple pieces of electrocardiogram (ECG) data respectively corresponding to a coronary artery set; generating multiple first probabilities corresponding to the multiple pieces of electrocardiogram data respectively according to the multiple pieces of electrocardiogram data and a first phase model, generating a first determined result according to the multiple first probabilities, and selecting a first data subset corresponding to a first probability subset from the multiple pieces of electrocardiogram data in response to each one in the first data subset of the multiple first probabilities being greater than a first threshold; generating multiple second probabilities corresponding to the first data subset according to the first data subset and a second phase model, and generating a second determined result according to the multiple second probabilities.

Abstract: An electronic device and a method for selecting a feature of an electrocardiogram (ECG) are provided. The method includes: obtaining the ECG; performing a first pre-processing on the ECG to generate a first ECG; marking multiple extreme points corresponding to at least one type of wave on the first ECG; calculating a first feature value corresponding to a first feature according to the multiple extreme points of the at least one type of wave, generating a first performance index corresponding to a machine learning model according to the first feature value, and determining whether to select the first feature according to the first performance index; and outputting the first feature in response to selecting the first feature.

Abstract: An electronic device and a method for screening features for predicting a physiological state are provided. The method includes: obtaining multiple physiological data corresponding to multiple features; generating multiple first subsets of the multiple features according to the multiple physiological data based on a first model, wherein the multiple first subsets respectively correspond to the multiple physiological data; selecting a first feature from the multiple features according to the multiple first subsets, calculating a first relation index of the first feature and a second feature corresponding to the multiple features, and selecting the second feature as an accompanied feature of the first feature according to the first relation index; and outputting the first feature and the accompanied feature.

Abstract: The present invention provides novel substituted benzimidazole derivatives of formula (I) used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

Abstract: A method for identifying an AhR-phospho-ROR?t protein complex inhibitor, comprising: (a) providing a cell culture, in which cells in the culture express AhR protein and phospho-ROR?t protein; (b) incubating the cell culture in the presence of a test agent; (c) assaying the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent; (d) comparing the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent with a control; and (e) identifying the test agent as the inhibitor of the AhR-phospho-ROR?t protein complex when the comparing step indicates that there is a reduction in the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent as compared with the control. A method for identifying a GLK?IQGAP1 protein complex inhibitor is also disclosed. Use of identified inhibitors in the manufacture of a medicament for treating a disease is also disclosed.

Abstract: Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: wherein R1 and R2 are defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.

Abstract: The present application provides a method for genotyping M. tuberculosis, comprising obtaining amplifying and obtaining a first DNA fragment from a DNA sample by using one or more primer sets selected from the group consisting of primer sets 1 to 25 (SEQ ID Nos. 1 to 50); amplifying and obtaining a second DNA fragment from the obtained first DNA fragment by using one or more extension primers selected from the group consisting of SEQ ID Nos. 51 to 75; and detecting the second DNA fragment by using mass spectrometry, particularly by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Abstract: Provided is a pharmaceutical composition, including an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. Also provided is a method of enhancing immunogenicity of an antigen, including conjugating the antigen with an antagonist of an Fc gamma receptor to form an antigen fusion protein. Also provided is a method of enhancing an immune response to an antigen in a subject, including administering to the subject an effective amount of an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. The present invention may be applied in the development of potent vaccines based on targeting vaccine antigens to antigen-presenting cells via binding to Fc gamma receptors.

Abstract: The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative.

Abstract: Provided a method for separating PHA and PHA prepared therefrom. The method comprises the following steps: subjecting a PHA fermentation broth to solid-liquid separation to obtain a thallus precipitate; breaking cell walls of the thallus precipitate, and subjecting obtained wall-broken products to a plate and frame filtration to obtain PHA; a filter cloth for the plate and frame filtration is pre-coated with a PHA layer. The method adopts a plate and frame separation to replace the traditional centrifugal separation to prepare PHA, and the PHA layer is pre-coated on the filter cloth for the plate and frame filtration, thereby overcome the defects in the prior art such as high cost and operational difficulty caused by adopting multiple centrifugal separations; in addition, the method of the present disclosure also exhibits the advantages of high recovery rate of PHA and high purity of the prepared PHA product.

Abstract: The present invention relates to the field of high polymer material manufacturing, and discloses an air-isolated continuous feeding system for synthesizing polylactic acid from lactide and a feeding method thereof. The continuous feeding system comprises a raw material bag/box and a raw material collector for collecting and outputting lactide, the raw material bag/box is connected with a shielding gas input pipeline, a discharge pipe is movably inserted into the raw material bag/box, a cyclone separator is connected downstream of the discharge pipe, and a solid substance outlet of the cyclone separator is connected with the raw material collector. According to the invention, deterioration of the lactide raw material incurred by moisture absorption and oxidation is avoided, and the reaction conversion ratio and final product purity are improved. The continuous feeding system is easy to operate, can save manpower and material resources, and is applicable to industrial application.

Abstract: The present invention relates to the field of high polymer material manufacturing, and discloses an air-isolated continuous feeding system for synthesizing polylactic acid from lactide and a feeding method thereof. The continuous feeding system comprises a raw material bag/box and a raw material collector for collecting and outputting lactide, the raw material bag/box is connected with a shielding gas input pipeline, a discharge pipe is movably inserted into the raw material bag/box, a cyclone separator is connected downstream of the discharge pipe, and a solid substance outlet of the cyclone separator is connected with the raw material collector. According to the invention, deterioration of the lactide raw material incurred by moisture absorption and oxidation is avoided, and the reaction conversion ratio and final product purity are improved. The continuous feeding system is easy to operate, can save manpower and material resources, and is applicable to industrial application.

Abstract: Provided a method for separating PHA and PHA prepared therefrom. The method comprises the following steps: subjecting a PHA fermentation broth to solid-liquid separation to obtain a thallus precipitate; breaking cell walls of the thallus precipitate, and subjecting obtained wall-broken products to a plate and frame filtration to obtain PHA; a filter cloth for the plate and frame filtration is pre-coated with a PHA layer. The method adopts a plate and frame separation to replace the traditional centrifugal separation to prepare PHA, and the PHA layer is pre-coated on the filter cloth for the plate and frame filtration, thereby overcome the defects in the prior art such as high cost and operational difficulty caused by adopting multiple centrifugal separations; in addition, the method of the present disclosure also exhibits the advantages of high recovery rate of PHA and high purity of the prepared PHA product.

Abstract: The invention provides a nanoemulsion adjuvant and a preparation method thereof, which are composed of the following components: a continuous aqueous phase containing H2O molecules, an oil phase material containing fats and oils, and an emulsion system for stabilizing the interface between the continuous aqueous phase and the oil phase, and the emulsion system is an emulsifier mixture. The adjuvant is characterized in that the emulsion system does not contain an ionic emulsifier and the particle size of the emulsion is between 20 and 200 nanometers. The use of the nanoemulsion adjuvant can prevent toxicity and possible harm of ionic emulsifiers to human cells, and provide a vaccine preparation capable of eliciting a high degree of immune response.

Abstract: A method for efficiently producing PHA comprising: inoculating PHA fermentation strains into a fermentation medium for fermentation under the condition of being capable of producing PHA through fermentation; subjecting the fermentation broth to a solid-liquid separation to obtain fermentation supernatant and thallus precipitate; breaking the cell walls of the thallus precipitate, and subjecting the wall-broken products to a plate and frame filtration to prepare PHA; pre-coating a filter cloth for the plate and frame filtration with a PHA layer; at least part of the water of the fermentation medium is PHA process wastewater. The method utilizes the PHA process wastewater as at least part of the water of the fermentation medium, and filters and separates the broken thallus with the plate and frame filtration equipment pre-coated with PHA layer to prepare PHA, thereby recycling the high-salt wastewater, reducing costs, and potentially separating PHA on a large scale for industrial production.

Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.